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Abstract
Background: Acute renal failure (ARF) is an important clinical problem with a high mortality and morbidity. One of
the primary causes of ARF is ischemia/reperfusion (I/R). Inflammatory process and oxidative stress are thought to
be the major mechanisms causing I/R. MK-886 is a potent inhibitor of leukotrienes biosynthesis which may have
anti-inflammatory and antioxidant effects through inhibition of polymorphonuclear leukocytes (PMNs) infiltration
into renal tissues. 3, 5-diiodothyropropionic acid (DITPA) have evidences of improving effects on I/R in heart
through modulation of cellular signaling in response to ischemic stress. The objective of present study was to
assess the effects of MK-886 and DITPA on renal I/R injury.
Methods: A total of 24 Adult males of Swiss albino mice were randomized to four groups: I/R group (n = 6), mice
underwent 30 minute bilateral renal ischemia and 48 hr reperfusion. Sham group (n = 6), mice underwent same
anesthetic and surgical procedures except for ischemia induction. MK-886-treated group: (n = 6), I/R + MK-886 (6
mg/kg) by intraperitoneal injection. DITPA-treated group: (n = 6), I/R + DITPA (3.75 mg/kg) by intraperitoneal
injection.
After the end of reperfusion phase mice were sacrificed, blood samples were collected directly from the heart for
determination of serum TNF-a, IL-6, urea and Creatinine. Both kidney were excised, the right one homogenized for
oxidative stress parameters (MDA and GSH) measurements and the left kidney fixed in formalin for histological
examination.
Results: Serum TNF-a, IL-6, urea and Creatinine, kidney MDA levels and scores of histopathological changes were
significantly (P < 0.05) elevated in I/R group as compared with that of sham group. Kidney GSH level was
significantly (P < 0.05) decreased in I/R group as compared with that of sham group. MK-886 treated group has
significantly (P < 0.05) lowered levels of all study parameters except for GSH level which was significantly (P < 0.05)
higher as compared with that of I/R group. DITPA caused non-significant (P > 0.05) changes in levels of all study
parameters as compared with that of I/R group.
Conclusion: The results of the present study show that MK-886 significantly ameliorated kidney damage that
resulted from I/R. For DITPA, as its administration might not be successful, administration using a different protocol
may give different effects on I/R.
Background
Acute kidney injury (AKI) is a common clinical syn-
drome characterized by rapid deterioration of renal
function. AKI can be classified into three categories,
namely, prerenal, intrinsic, and postrenal acute kidney
injury. Progressive AKI leads to acute renal failure
(ARF)[1]. ARF is an important clinical problem with a
high mortality and morbidity. It affects 5% of hospita-
lized patients and has a mortality rate of approximately
50%[1]. One of the primary causes of ARF is I/R which
is a drop in blood flow leading to inadequate supply of
oxygen and nutrients to renal tissue which can be
caused by, amongst others, surgery, organ transplanta-
tion and shock [1].
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accompanying oxygen radical-mediated injury is the
main event that leads to injury; under ischemic condi-
tions, reduced oxygen supply leads to enhanced neutro-
phil adherence to tubular endothelial cells [2-4] due to
increased surface expression of adhesion molecules on
tubular endothelial cells [2,4,5]. This ultimately results,
on reperfusion, in diapedesis of neutrophils and their
oxidative burst, which results in oxygen radical produc-
tion [6,7]. So in addition to the direct cytotoxic effects
of hypoxia, renal I/R induces an inflammatory reaction
within the renal parenchyma [8] by causing renal synth-
esis of pro-inflammatory cytokines such as Interleukin
(IL)-1, IL-6, IL-18, and tumor necrosis factor (TNF)-a
[9-12].
Many of the reactive oxygen species (ROS) produced
by I/R activate the signaling mechanisms that culminate
in TNF-a production [13]. TNF-a is a proinflammatory
cytokine capable of up regulating its own expression, as
well as the expression of other genes important in the
inflammatory response [14]. TNF-a and I/R increase
iNOS activity to synthesize nitric oxide [15,16]. Nitric
oxide production (by iNOS) may play several roles in
renal pathophysiology, including induction of tubular
damage. Prevention or reduction of nitric oxide genera-
tion reduces nitric oxide-induced renal injury [17], and
the increased generation of nitric oxide is capable of
inducing intracellular oxidizing reaction and cell death
[18].
I/R injury of the kidney is characterized by a series of
events, including changes in vascular tone, enhanced
vascular permeability to plasma proteins, structural
alterations in renal tubule and accumulation of activated
neutrophils [19]. The cysteinyl LT, LTC4,L T D 4,a n d
LTE4, affect the tonus of the arterioles and the perme-
ability of postcapillary venules, thereby causing endothe-
lial contraction and macromolecular leakage [20].
LTB4 is a mediator in the pathophysiology of the renal
dysfunction caused by I/R of the kidney as well as the
associated infiltration of the kidney with PMNs [21].
LTB4 activates PMNs, thus changing their shape and
promoting their binding to endothelium by inducing the
expression of cell-adhesion molecules. After PMN trans-
migration into ischemic renal tissue, PMNs release reac-
tive oxygen species, proteases, elastase, myeloperoxidase
(MPO), cytokines, and various other mediators [19], all
of which exacerbate inflammation and contribute to tis-
sue injury (positive feedback). For instance, ROS will
react with the polyunsaturated membrane lipids [22],
and lipid peroxidation, in turn, will enhance the tissue
levels of free arachidonic acid [23].
A potent and selective inhibitor of 5-lipoxygenase acti-
vating protein (FLAP) is MK-886[24]which binds to
FLAP with high affinity and prevents the activation of
5-lipoxygenase. MK886 is a highly selective compound
with no effects on prostaglandin synthesis [25]. It does,
however, inhibit translocation of 5-LOX [26].
Blocking leukotrienes was showen to be effective in
improving I/R damage in liver, intestines [27] and also
kidney (not by MK-886)[28] by inducing anti-inflamma-
tory and antioxidant effects [27,28]. Therefore, in this
study, we studied the effect of MK-886 on kidney injury
and studied if MK-886 can exert anti-inflammatory and
antioxidant properties through renal I/R injury.
Studies in animal and cell-based models give evidences
that acute or chronic pretreatment with TH before I/R
can protect from I/R injury [29]. The protective effect of
acute T3 pretreatment was shown in an ex vivo canine
heart preparation and in another study a model of rat
heart in which cardiac work and cardiac efficiency were
found to increase after no flow global I/R [30,31]. Simi-
larly, long-term pretreatment with l-thyroxine for 2
weeks or T3 for 10 days was also shown to improve
postischaemic recovery of function in isolated rat hearts
subjected to zero-flow global I/R [32,33].
This protective effect may occur by attenuating the I/
R-induced activation of the pro-apoptotic p38 Mitogen-
activated protein kinases (MAPKs) by either negative
regulation of Protein kinase C (PKCδ) or by decreased
phosphorylation due to reduced ATP availability (due to
reduced glycogen content which occurs during ischemia
in hyperthyroid hearts) because stress kinases cannot be
phosphorylated by upstream kinases without ATP [34].
3, 5-diiodothyropropionic acid (DITPA) is a synthetic
TH-related compound with low metabolic activity which
binds both nuclear TR isoforms with decreased affinity
(Kd, 10
-7 M)[35]. In addition, DITPA binds integrin a
Vb3 through which it mediate angiogenesis [36].
Administration of DITPA after myocardial infarction in
rabbits improved post-infarct recovery function [37].
Also In a rabbit post-infarction model, use of DITPA
prevented abnormal sarcoplasmic reticulum Calsium
transport and abnormal contractile function associated
with myocardial infarction [38].
Based on these encouraging results about the effect of
DITPA in experimental models of I/R in heart, in this
study the effect of DITPA on I/R in kidney was studied.
Methods
A total of 24 adult male of Swiss Albino mice (weighing
30-35 g, aged 12 weeks) were purchased from Animal
Resource Center, the Institute of embryo research and
treatment of infertility, Al-Nahrain University. All
experiments were approved by the Animal Care and
Research Committee of the University of Kufa, and this
investigation conforms with the Guide for the Care and
Use of Laboratory Animals (National Research Council).
Animals were housed in the animal house of College of
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(24 ± 2°C) room with alternating 12-h light/12-h dark
cycles and were allowed free access to water and diet
until the start of experiments. After one week of accli-
matization, the mice were randomized into four groups
(6 mice in each group) as follow:
-Ischemia/reperfusion group: mice underwent ische-
mia for 30 minute then reperfusion for 48 hours.
- S h a mg r o u p :m i c eu n d e r w e n tt h es a m ea n e s t h e t i c
and surgical procedures and received the same volumes
of vehicles (for an identical period for ischemia and
reperfusion) except for ischemia induction.
-MK-886-treated group: mice received MK-886
(Cyman chemical, USA) in a dose of 6 mg/kg by intra-
peritoneal injection, 30 min before the induction of
ischemia, and the same dose was repeated just before
reperfusion period. The drug prepared immediately
before use as a homogenized solution in 2% ethanol [39]
(not more than 0.1 ml was injected).
-DITPA-treated group: Mice received DITPA (Sigma
chemical, USA) in a dose of 3.75 mg/kg by intraperito-
neal injection, 30 min before the induction of ischemia,
and the same dose was repeated just before reperfusion
period. Solution of DITPA was prepared immediately
before use by dissolving the powder in 0.1 N NaOH and
diluting with 0.9% saline (pH 9)[40] (not more than 0.1
ml was injected).
Induction of I/R
Animals were intraperitoneally anesthetized with 100
mg/kg ketamine and 10 mg/kg xylazine [41]. According
to Sharyo et al (2009)[42], after anesthesia, an abdom-
inal incision was made and the renal pedicles were dis-
sected bilaterally. A vascular clamp (Biotechno,
Germany) was placed on each renal pedicle for 30 min.
After clamps were released, the incision was closed in
two layers with 2-0 sutures and mice were returned
back to their cages and left for 48 hr for reperfusion.
Sham operations were conducted using the same proce-
dure without placing a clamp on each renal pedicle.
After the end of reperfusion phase mice were sacrificed
using over dosing of anesthesia, blood samples were
taken directly from the heart, both kidneys were excised,
the right one homogenized then kept in deep freeze at -
80°C for oxidative stress measurement and the left kid-
ney fixed in 10% neutral buffered formalin for histologi-
cal examination.
Inflammatory and Kidney Function Markers
At 48 hr after ischemia induction, (at the end of reper-
fusion period), from each mouse about 1.5 ml of blood
was collected from the heart. The blood samples were
allowed to clot at 37°C and centrifuged at 3000 rpm for
15 min; Sera were removed, and analyzed for
determination of serum TNF-a, IL-6 (using ELISA kits
of Immunotech, France), urea (using kit of BioMĕr-
ieux
®sa, France) and Creatinine (using kit of Spinreact,
Spain).
For IL-6, Samples and calibrators were incubated in
the microtiter plate coated with the first monoclonal
antibody anti-IL-6, in presence of the second anti-IL-6
monoclonal antibody linked to acetylcholinesterase
(ACE). After incubation, the wells were washed and the
bound enzymatic activity is detected by addition of a
chromogenic substrate. The intensity of the coloration is
proportional to the IL-6 concentration in the sample or
calibrator.
￿ Reagents provided
-Plate: 12 × 8 wells
-Calibrator: one vial contains lyophilized bovine serum
albumin
-IL-6 ACE conjugate: one vial contains lyophilized
bovine serum albumin
-Diluent 1: one 25 mL vial contains bovine serum
albumin.
-Diluent 2: one vial contains lyophilized material of
murine origin
-Wash solution (20×): one 50 mL vial
-Substrate: one vial
-Stop solution: Stop solution is a tacrine solution.
-Specificity: murine IL-6
- Dilution: firstly 1/10 then 1/3 for four times dilu-
tions for standard (calibrator).
For TNF-a, Samples and calibrators are incubated in
the microtiter plate coated with the first monoclonal
antibody anti-TNF-a, in presence of the second anti-
TNF-a monoclonal antibody linked to alkaline phospha-
tase. After incubation, the wells were washed and the
bound enzymatic activity is detected by addition of a
chromogenic substrate.
￿ Reagents provided
-Plate: 12 × 8 wells
-Calibrator: one vial contains lyophilized bovine serum
albumin
-TNF-a conjugate: one vial contains lyophilized
bovine serum albumin
-Diluent 1: one 25 mL vial contains bovine serum
albumin.
-Diluent 2: one vial contains lyophilized material of
murine origin.
-Wash solution (20×): one 50 mL vial
-Substrate buffer: one 30 mL vial of diethanolamine-
HCl solution.
-Substrate: two tablets
-Stop solution: one 6 mL vial of NaOH 1 N solution.
-Specificity: murine TNF-a
-firstly 1/10 then 1/4 for three times dilutions for
standard.
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The whole kidney tissues were homogenized with a
high intensity ultrasonic liquid processor in 1:10 (w/v)
0.1 M potassium phosphate buffer (pH7.4). The 10%
homogenates were centrifuged at 10, 000 rpm for 10
min at 4°C and supernatants were used for determina-
tion of GSH and MDA levels [43]. GSH kidney level (as
an indices of antioxidant status) was measured using
Quantichrom™Glutathione assay Kit (from BioAssay
Systems, USA). MDA, the end product of lipid peroxida-
tion, was analyzed according to the method of Buege
and Aust in 1978[44] which based on the reaction of
MDA with thiobarbituric acid (TBA) to form MDA-
TBA complex, a red chromophore, which can be quanti-
tated spectro-photometrically according to this method.
￿ Preparation of TBA reagent
-0.375 gm of TBA was added to 75 ml of DW.
- 15 gm of trichloroacetic acid (TCA) were added to
DW.
- 2.1 ml of 11.9 N Hydrochloric acid (HCL) were
added to DW.
- The solution completed up to 100 ml of DW.
￿ Procedure
-1 ml of kidney homogenate was added to 2 ml of TBA
reagent and mixing.
-The mixture was heated by water bath at (100°C) for
(15 min).
-Cooled and then centrifuged at 3000 rpm for (10
min).
- Light absorbance of clear supernatant was deter-
mined at 535 nm against blank using spectrophotomer.
￿ Calculation
The concentration of MDA =
absorbanceat 535nm
ε
× D
ε: Extinction coefficient = 1.56 × 10
5 M
-1 Cm
-1
D: Dilution factor
The results were expressed as nmol MDA/g tissue.
Histopathological Evaluation
Renal sections were examined by light microscopy and
scored according to a semiquantitative scale designed
according to Asaga et al (2008)[45] to evaluate the
severity of renal damage by a pathologist who was una-
ware of the treatment conditions. The slide section
divided into 10 intersections. A score from 0 to 3 was
given for each tubular profile involving each intersection
as the following: 0 = normal histology; 1 = tubular cell
swelling, brush border loss, nuclear condensation, with
less than one-third of the tubular profile showing
nuclear loss; 2 = same as for score 1, but greater than
one-third and less than two-thirds of the tubular profile
showing nuclear loss; and 3 = greater than two-thirds of
the tubular profile showing nuclear loss. Then the total
score for each kidney (section) was calculated by the
summation of the all 10 scores for the all 10 intersec-
tions with a maximum Score of 30. According to the
total severity score, the kidney injury was classified to
normal (0), mild (1-10), moderate (11-20) and severe
injury (21-30).
Statistical analysis
Statistical analyses were performed using SPSS 12.0 for
windows.lnc. Data were expressed as mean ± SEM. Ana-
lysis of Variance (ANOVA) was used for the multiple
comparisons among all groups followed by post-hoc
tests using LSD method. For the histopathological renal
changes, the Mann-Whitney U was used to assess the
statistical significance of difference between two groups
in total severity score. In all tests, P < 0.05 was consid-
ered statistically significant.
Results
Effects on inflammatory parameters
I/R caused significant (P < 0.05) elevation in serum
TNF-a a n dI L - 6l e v e l sa sc o m p a r e dw i t ht h a to fs h a m
group. MK-886 significantly inhibited the elevated levels
observed in I/R group. DITPA cause non-significant
changes in serum TNF-a and IL-6 levels as compared
with that of I/R group (see Figure 1).
Effects on kidney function parameters
I/R caused significant (P < 0.05) elevation in serum urea
and creatinine levels as compared with that of sham
group. MK-886 significantly inhibited the elevated levels
observed in I/R group. DITPA cause non-significant
changes in serum urea and creatinine levels as com-
pared with that of I/R group (See Figure 2).
Effects on oxidative stress parameters
I/R caused significant (P < 0.05) elevation in kidney
MDA level and significant (P < 0.05) reduction in kid-
ney GSH level as compared with that of sham group.
MK-886 significantly inhibited the elevated kidney
MDA level and significantly increased the reduced
kidney GSH level observed in I/R group. DITPA
cause non-significant changes in kidney MDA and
G S Hl e v e l sa sc o m p a r e dw i t ht h a to fI / Rg r o u p( s e e
Figure 3).
Effects on Histology
The fallowing photomicrographs will show intersections
of different severity scores obtained at the 48 hr after I/
R (Figure 4).
Histopathological changesr e s u l t e da tt h ee n do ft h e
study would be mentioned in table 1 and Figure 5. In
sham group, most of slide sections of kidneys of mice in
this group showed normal grading (normal
architecture).
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this group showed severe grading. Mean of total severity
scores of the sections of this group significantly higher
than that of Sham group (P = 0.003). Treatment with MK-
886 caused significant amelioration in kidney injury as
seen by significant lowering in total severity scores of the
sections of this group as compared with that of I/R group
(p = 0.004). DITPA failed to get significant lowering
In total severity scores of the sections of this group as
compared with that of I/R group (p = 0.292).
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Figure 1 Error bar charts show the difference in mean ± SEM values of serum IL-6 and TNF-a levels (pg/ml) in the four experimental
groups at 48 hr after surgical operation (N = 6 in each group). * p < 0.05 when compared with sham group. ** p < 0.05 when compared
with I/R group.

  
 

 

Figure 2 Error bar charts show the difference in mean ± SEM values of serum urea and creatinine levels (pg/ml) in the four
experimental groups at 48 hr after surgical operation (N = 6 in each group). * p < 0.05 when compared with sham group. ** p < 0.05
when compared with I/R group.
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Effects of Ischemia/Reperfusion
This study shows that IL-6 and TNF- a was significantly
i n c r e a s e d( P<0 . 0 5 )t om o r et h a nt h a to fs h a mg r o u p
after I/R. Several studies show that I/R caused renal
synthesis of the pro-inflammatory cytokines [9-12]. An
explanation of this was that these cytokines are primar-
ily produced by macrophage [46-48] and that I/R cause
infiltration of macrophage to the kidney parenchyma
[49]. Takada et al (1997)[9] were examined the initial
(within 7 days) events of warm and in situ perfused cold
ischemia of native kidneys in uninephrectomized rats.
mRNA expression of the early adhesion molecule, E-
selectin, peaked within 6 h; PMNs infiltrated in parallel.
T cells and macrophages entered the injured kidney by
2-5 days; the associated upregulation of MHC class II
antigen expression suggested increased immunogenicity
of the organ. Th1 products (IL-2, TNF-a,I F N g)a n d
macrophage-associated products (IL-1, IL-6, TGF-b)
remained highly expressed after 2 days [9]. For IL-6,
Kielar et.al 2005[50] found that in mouse model of
ischemic renal injury, macrophages infiltrate the area of
the vascular bundles of the outer medulla, these macro-
phages produce IL-6, and this IL-6 exacerbates ischemic
murine acute renal failure [50]. Also Sharyo et al
(2009)[42] found that serum IL-6 was elevated after 24
hr of reperfusion in 30 min ischemia and 48 hr reperfu-
sion in mice [42].
I/R caused significant increase in oxidative status
(increased generation of ROS). This finding agree with
that in other studies: Mejía-Vilet et al (2007)[51] tested
the effect of spironolactone on I/R rat model (20 minute
*,**

*

Figure 3 Error bar charts show the difference in mean ± SEM values of kidney MDA (nmol/gtissue)a n dG S H( μmol/gtissue)i nt h ef o u r
experimental groups at 48 hr after surgical operation (N = 6 in each group). * p < 0.05 when compared with sham group. ** p < 0.05
when compared with I/R group.
Table 1 The differences in histopathological grading of kidney changes among the four study groups at 48 hr after
surgical operation.
Histopathological Study groups
changes grading Sham I/R MK-886 DITPA
N%N%N% N %
Normal 4 66.6 0 0 1 16.6 0 0
Mild 2 33.4 0 0 3 50 1 16.6
Moderate 0 0 2 66.6 2 33.4 3 50
Severe 0 0 4 33.4 0 0 2 33.4
Total 6 100 6 100 6 100 6 100
Grade of the group Normal Severe Mild Moderate
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found that kidney MDA was significantly increased with
significant decrease in kidney GSH in I/R group as com-
pared with sham group [51]. Seok et al (2007)[52] show
that I/R in mouse model (30 minute bilateral renal
ischemia and 48 hours reperfusion) causing significant
increase in kidney MDA and kidney GSH decrease [52].
In particular, at the onset of reperfusion, organs are
exposed to an injurious burst of oxygen free radicals
[53]. Natural antioxidant defenses may be overwhelmed
and thus allow the oxygen radicals to exert their deleter-
ious effects without control. Inflammatory cells involved
in the damage produce more oxygen radicals, which
increase the gravity of the initial injury [54]. This excess
in ROS will lead to overcome antioxidant mechanisms
and causing low level of tissue GSH and increased per-
oxidation of lipids and causing high tissue level of MDA
(end product of lipid peroxidation)[55,56].
I/R caused significant impairment in kidney function
as compared with that of sham group (due to low glo-
merular filtration rate [57]). I/R caused significant kid-
ney injury due to IR-induced ROS production and nitric
oxide in tubular epithelial cells beyond the scavenging
capacity, and led to excessive ROS- and nitric oxide
[19]-induced lipid peroxidation, DNA damage, and pro-
tein dysfunction leading to renal structural and func-
tional impairment [18,19]. Also adhesion, activation, and
transmigration of polymorphonuclear leukocytes
(PMNs) into renal tissues and their oxidative burst
resulted in excessive ROS production and worsening
kidney damage (neutrophil-mediated tissue injury)
[14,19]. Another mechanism is that TNF-a can cause
renal tissue damage by direct cytotoxicity (induction of
dysfunction and/or apoptosis)[58]. Sharyo et al (2009)
[42] also showed significant increase in serum urea and
creatinine levels after 30 min bilateral renal ischemia
$ % 
& 
' 
Figure 4 Photomicrographs of kidney intersections; A show score 0; B show score 1; C show score 2; D show score 3. Sections stained
with haematoxylin and Eosin (X 400).
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showed that I/R in mouse model (30 minute bilateral
renal ischemia and 48 hours reperfusion) revealed a
severe loss of brush borders in the proximal tubular
epithelial cells was observed, as well as luminal conges-
tion, tubular atrophy, and tubular dilation in the outer
medulla of the I/R mice [52].
Effects of MK-886
The present study showed that the effect of use of MK-
886 (6 mg/kg) before induction of ischemia and at the
onset of reperfusion caused significant lowering (P <
0.05) in serum levels of the IL-6 and TNF-a. This could
be explained by that MK-886 is a potent and selective
inhibitor of FLAP [24]. So inhibit the biosynthesis of
LTs including cysteinyl LTs and non cysteinyl LT
(LTB4)[59]. Poubelle et al (1991)[60] clarify that LTB4
stimulated preferentially IL-6 production and that the
observed LTB4-induced augmentation in thymocyte
responses to monocyte supernatants is due to augmen-
ted IL-6 contents in the presence of baseline minimal
IL-1 production [60]. Rola-Pleszczynski et al (1992)
[61] reported that When human monocytes were cul-
tured in the presence of graded nanomolar concentra-
tions of LTB4, significant stimulation of production of
bioactive and immunoreactive IL-6 was observed [61].
IL-6 regulates the expression of adhesion molecules and
other cytokines in endothelial cells including IL-1b and
TNF-a w h i c hi nt u r np o t e n t l ye n h a n c et h e
inflammatory response [62]. So inhibiting LTB4 synth-
esis (by MK-886) resulted in significant inhibition in IL-
6a n dT N F - a production. This conclusion about MK-
886 effect on IL-6 and results obtained from the present
study about effect of MK-886 in lowering IL-6 and
TNF-a are consistent with that reported by Cannetti et
al (2003)[63]that In an IL-18-dependent murine col-
lagen-induced arthritis model, MK-886-treated mice dis-
played suppressed proinflammatory cytokine (IL-6 and
TNF-a) production [63]. In that study, they mentioned
that MK-886 act on IL-6 and TNF-a by the same
mechanism supposed in this study although in different
models.
MK-886-received animals had significant lower oxida-
tive status (decreased generation of ROS) than that in I/
R group animals. Noiri et al (2000)[21] demonstrated
that LTB4 played a pivotal role in the recruitment of
PMNs in kidneys subjected to I/R, and LTB4 receptor-
antagonists abolished the PMN accumulation after I/R
of the kidney [21]. Inhibiting LTB4 synthesis by MK-886
caused inhibition of activation of PMNs and their bind-
ing to endothelium by inhibiting the expression of cell-
adhesion molecules and so block PMN infiltration into
ischemic renal tissue, so inhibit release of ROS, pro-
teases, elastase, myeloperoxidase (MPO), cytokines and
various other mediators [19]. Also blocking the CysLTs
synthesis, which are responsible of increased permeabil-
ity, and thus, recruitment of neutrophils and macro-
phages, which are the producers of the pro-
*,** 
* 
Figure 5 Error bar chart shows the difference in mean ± SEM values of total severity scores in the four experimental groups at 48 hr
after surgical operation (N = 6 in each group). * p < 0.05 when compared with sham group. ** p < 0.05 when compared with I/R group.
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inhibition of ROS release so less lipid peroxidation, less
MDA level and less consumption of GSH and higher
r e n a lG S Hl e v e l .B yt h es a m em a n n e rDaglar et al
(2009)[27], in hepatic I/R in rat model, demonstrated
that Inhibition of LTs action by montelukast or MK-886
has protective effects against I/R injury by reducing
apoptosis and inhibition of ROS generation [27].
In this study, MK-886 causes significant preservation of
renal function by inhibiting LTB4 and CysLTs synthesis,
blocking PMN infiltration into ischemic renal tissue, so
inhibiting the release of ROS and less TNF-a[13] so less
production of NO (by inhibiting iNOS) so abolish lipid
peroxidation, DNA damage, and protein dysfunction,
leading to significant protection from renal structural
and functional impairment [18,19]. Şener et al (2006)
[28] showed that in rat model of I/R, Montelukast (10
mg kg
-1, i.p.) administration at 15 min prior to ischemia
and immediately before the reperfusion period caused
significant lowering in creatinine and urea as compared
with that of I/R group [28]. Also in the same study, mon-
telukast significantly protected kidney parenchyma from
severe damage observed in I/R group by inhibiting neu-
trophil infiltration, and regulating the generation of
inflammatory mediators and ROS [28]. So it is not sur-
prising for MK-886 to have protective effect on kidney
parenchyma as it antagonizes the effect of not only the
cystLTs but also LTB4 by inhibiting their biosynthesis.
It was noted that the renal injury and dysfunction
observed in mice after I/R were not entirely abolished in
mice received MK-886, the degree of inhibition of ele-
vated serum urea and creatinine was not as complete as
that of sham group. This is not surprising, given that
many other pathophysiological mechanisms, which are
independent of LTs and/or an enhanced inflammatory
response, contributed to the observed injury during
ischemia and/or reperfusion. These mechanisms may
include (but are not limited to), modification of endo-
genous lipoxin generation [64] or the activation of the
nuclear enzyme poly (ADP-ribose) polymerase [65].
Effects of DITPA
To the best of our knowledge, this is the first study that
used DITPA in model of renal I/R but TH (whether by
acute T3 pretreatment or by long-term pretreatment
with l-thyroxine)[31,32] and also DITPA were used in
many models of I/R in several organs other than kidney
and observed protective and/or improving action [37].
The possible mechanisms that underlie TH-induced
cardioprotection are that Complex intracellular signal-
ling underlies the cellular response to stress and the bal-
ance between pro-death and pro-survival pathways
seems to determine cellular fate after an ischaemic
insult. JNK kinases are thought as a pro-death signaling
(in response to stressful stimuli). It was inhibited due to
decreased phosphorylation due to reduced ATP avail-
ability (because of the reduced glycogen content which
occurs during ischemia in hyperthyroid hearts)[34]. In
the present study, DITPA, which has low metabolic
activity, would not cause enough effect on ATP avail-
ability and so no inhibition of pro-death signals that is
required to protect the kidney.
When myocardial ischemia was severe and induced
irreversible damage, the improved post infarction func-
tion recovery by THs or DITPA may be mainly by their
angiogenic action [36,66]. This action may have no role
to play in reversible renal I/R model when inflammation
play the major role in inducing injury and may explain
why DITPA failed to exert protective effect in the rever-
sible I/R model in this study.
Administration of DITPA after myocardial infarction
in rabbits improved post-infarct recovery function [37].
Also In a rabbit post-infarction model, use of DITPA
prevented abnormal sarcoplasmic reticulum Calcium
transport (that mediate necrosis and permanent injury)
in myocardial infarction [38]. So DITPA may not inter-
fere with reversible I/R model in which inflammation
rather than calcium dyshomeostasis have major role to
play to cause tissue damages.
In an organ other than heart, Fernández et al (2006)
[67]showed that the use of T3 in I/R in liver (1 hr ische-
mia and 20 hr reperfusion) causing transient oxidative
stress in the liver (occurred within a period of 36 hours
of T3 treatment)[67]. This exerted significant protection
against I/R injury, a novel preconditioning maneuver that
is related to a gain of liver cell signaling functions repre-
sented by recovery of NF-Ba n dS T A T 3D N Ab i n d i n g
(NF-B and STAT3 activation) and acute-phase
response, which are lost during I/R. These responses may
protect the liver against I/R-induced oxidative stress by
re-establishing redox homeostasis [67]. Thyroid hormone
pretreatment (10 μg/100 g body weight) 48 hr before I/R
procedure significantly reduced parameters about oxida-
tive stress compared with that of I/R group and so pro-
tected kidney from severe injury [68]. In the present
study, DITPA administration was only 30 min prior to
ischemia induction to see if there was any anti-inflamma-
tory action for DITPA like that proved for MK-886
(before this study). This may be short time course to
exert preconditioning effect on oxidative stress similar to
that induced in hepatic and renal I/R injury in which T3
administration was 36 hr and 48 hr respectively prior to
ischemia induction [67,68] and this may give suggestion
for plane future in studying DITPA in I/R model.
Conclusion
The results of the present study show that MK-886 sig-
nificantly ameliorated kidney damage, resulted from I/R,
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Page 9 of 11by counteracting inflammatory and oxidative processes.
DITPA, by this protocol of administration, failed to
ameliorate kidney injury and the use of other adminis-
tration way may give different effect on renal I/R injury.
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